您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > JH-RE-06
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
JH-RE-06
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
JH-RE-06图片
CAS NO:1361227-90-8
规格:98%
分子量:468.72
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
JH-RE-06, 有效的 REV1-REV7 互作抑制剂 (IC50=0.78 μM; Kd=0.42 μM),靶向与 POLζ 的 REV7 亚基相互作用的 REV1。JH-RE-06 通过阻止诱变 POLζ 的募集来破坏诱变性跨损伤合成 (TLS)。JH-RE-06 增强顺铂诱导的细胞毒性,改善化疗效果。
CAS:1361227-90-8
分子式:C20H16Cl3N3O4
分子量:468.72
纯度:98%
存储:Store at -20°C

Background:

JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 enhances Cisplatin-induced cytotoxicity and improves chemotherapy[1][2]. IC50: 0.78 μM (REV1-REV7)[1]Kd: 0.42 μM (REV1-REV7)[1]


JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction[1].


JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines[1]. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice[1].


[1]. Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11. [2]. REV1-POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity. Cancer Discov. 2019 Aug;9(8):OF17.